Skip to Main Content

Clinically advanced non-invasive imaging acquisition for precise prostate cancer detection

OnQ Prostate is an FDA-cleared software solution using Restriction Spectrum Imaging (RSI), a patented diffusion MRI method that has been shown to improve detection, in vivo characterization, and localization of clinically significant cancer.

Improved accuracy for quality reads

Through clear, easy-to-interpret images OnQ™ Prostate empowers collaborative decision-making and enhances targeting for biopsy and therapy. Elevating clinical workflows that use MRI for prostate cancer detection, monitoring, and treatment, it helps bridge the gaps between radiologists and referring physicians.

Benefits

Detection and prediction

Of clinically significant cancer

Improved tumor conspicuity

And differentiation from non-tumor

Stronger histopathology correlation

Based on Gleason Score

OnQ™ Prostate outputs

OnQ™ Prostate achieves improved PI-RADS accuracy and inter-reader agreement.

A sample OnQ™ Prostate output

Shows areas of restricted diffusion with increased conspicuity compared to acquired and computed high b-value DWI

Automatically fuses the restricted signal with the T2 for anatomic localization.

AI radiology news

Stay up to date with the latest insights, advances and clinical applications

Subscribe